Hey pharma investors! 🚨 Pfizer (PFE) has had a wild post-pandemic ride—from $100B revenue glory to post-COVID slumps. The big question: Should you avoid PFE right now? The answer hinges on how it navigates its transformation and solve the "blockbuster drug drought." Let’s break down its risks, pipeline hopes, and whether it’s worth your watch!
$Pfizer(PFE)$has experienced significant ups and downs in recent years. The pharmaceutical giant achieved great success in the early stages of the pandemic, generating $100 billion in revenue in 2022 through its COVID-19 vaccines and treatments. However, as demand for COVID-related products declined and patents for other blockbuster drugs expired, both the company’s revenue and stock price have fallen. Currently, should investors avoid Pfizer? The key lies in the risks during its transition period.
Blockbuster Decline, Transition Relies on Pipeline
Pfizer is facing a critical turning point. Its blockbuster drug sales are sliding, and it urgently needs to refresh its product portfolio with new offerings to drive future growth. This depends entirely on the company’s internal R&D capabilities and external acquisition success.
Pfizer’s biggest current risk is that its future largely rests on the outcomes of its R&D pipeline and recent acquisitions—including Seagen, acquired for its oncology products, and Metsera, which brought a pipeline of obesity drugs. In its latest earnings report, Pfizer stated that this year will be crucial, with the launch of 20 key clinical trials.
Targeting the $100B Market: Promising Outlook for Weight-Loss Drugs
The obesity drug market is an area that could transform Pfizer. Currently dominated by Eli Lilly and Novo Nordisk, Pfizer aims to enter this high-demand sector through its acquisition of Metsera. Analysts predict that by the end of this decade, the weight-loss drug market will be nearly $100 billion—large enough for multiple pharmaceutical companies to generate blockbuster revenues.
The candidate drug Pfizer gained from the acquisition has a potential advantage of once-monthly dosing, compared to existing once-weekly therapies. Latest trial data supports this low-frequency dosing concept, and Pfizer plans to advance 10 Phase III clinical trials for the drug this year.
Despite the promising outlook, risks remain. For any pharmaceutical company, the biggest risk is the failure of candidate drug development. Pfizer’s revival now depends on numerous ongoing research projects; if key drugs like the aforementioned weight-loss drug hit development roadblocks, the company’s transition process will be set back, putting significant pressure on its stock price.
Should You Avoid Pfizer?
Despite the challenges, Pfizer is still worth watching given its rich pipeline of research projects. Even if some headwinds slow down the transition, they are unlikely to stop it. If several candidate drugs are approved in the next few years, it is expected to usher in a new era of growth for Pfizer.
Looking back to 2020, Pfizer partnered with BioNTech (BNTX) to develop the COVID-19 vaccine Comirnaty, which became the first product approved in the United States and achieved tremendous commercial success. As Comirnaty sales declined, the company’s overall revenue fell, and its stock price was also affected. However, Pfizer still has two marketed vaccines—pneumococcal vaccine Prevnar 20 and respiratory syncytial virus (RSV) vaccine Abrysvo—that generate considerable revenue.
In addition, Pfizer’s R&D pipeline includes multiple ongoing products such as Lyme disease vaccine PF-07307405. Beyond vaccines, the company also sells drugs for the treatment of various diseases such as autoimmune disorders and cancer, and pays an attractive dividend, making its stock still one of the choices for income-seeking investors.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Comments